Melodiol Global Health Limited

ME1

Melodiol Global Health Ltd. engages in the developing, register and commercializes pharmaceutical-grade cannabis and hemp-hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health. The firm develops cannabis, hemp-derived and other plant-based therapeutic, nutraceutical, and lifestyle products. The firm distributes pharmaceuticals internationally, specializing in the distribution of medicinal cannabis products across Australasia, and non-cannabis products in the United Kingdom and Europe. The company also develops and sells beauty and personal care products, produced using plant-based processes, including under the brands Green Goo, Southern Butter and Good Goo. Its segments include Europe, Canada and Asia Pacific. Its Europe segment includes Health House International Limited (HHI), UK division, which distributes pharmaceutical products, and Creso Pharma Switzerland GmbH, which includes the development and commercialization of its nutraceutical products located in Switzerland. Its Canada segment includes Mernova Medicinal Inc, a producer of cannabis products and sells under the Ritual brand.

ME1DE

Melodiol Global Health Ltd. develops, registers and commercializes pharmaceutical-grade cannabis and hemp-hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health. The firm is engaged in developing cannabis and hemp-derived therapeutic-grade nutraceuticals and medical cannabis products with a range of applications in both human and animal health. Its cannabidiol (CBD) plant-based nutraceutical products are non-psychoactive, as they only contain trace amounts of tetrahydrocannabinol (THC). Its product is offered under various brands, including Green Goo, Southern Butter, Good Goo, Ritual, impactive and cannaQIX, among others. The company cultivates and harvests cannabis plants through its subsidiary, Mernova Medicinal Inc. and supplies cannabis retail products throughout Canada. Through its wholly owned, Canada-based psychedelics subsidiary, Halucenex Life Sciences Inc., it is also focused on the development of synthetic and botanical psilocybin treatments for treatment-resistant post-traumatic stress disorder, and other mental health conditions.